Site Editor

Joyce F. Liu, MD, MPH

Advertisement

Advertisement

News

Timing of Cytoreductive Surgery Impacts Outcomes in Advanced Ovarian Cancer

Medical Literature

Relacorilant Added to Nab-Paclitaxel Benefits Patients With Platinum-Resistant Ovarian Cancer

News

ASCO 2025: A Noninvasive Diagnostic Tool for Ovarian Cancer

News

AACR 2025: Are OTTA-SPOT Scores an Accurate Prognostic Tool for Black Patients With Ovarian Cancer?

News

Translational Data From Early-Phase Trial of Novel Immunotherapy for Advanced Ovarian Cancer

News

Australian Clinical Trial to Assess Next-Generation Screening Test for Ovarian Cancer

Medical Literature

Do Ovarian Tumor Cells Sabotage Nearby Cells Using Long Noncoding RNA?

Videos

Daniela E. Matei, MD on Biology-Driven Therapy for Ovarian Cancer

Videos

Lainie P. Martin, MD, Antibody-Drug Conjugates and Ovarian Cancer

Advertisement

JNCCN Spotlights

Olaparib (Lynparza)

Bevacizumab (Avastin®)

(UPDATE) Niraparib (Zejula)

Trametinib (Mekinist®)—Low-Grade Serous Ovarian Carcinoma

View More

More

News

Update on Overall Survival in Phase III Trial of Niraparib for Advanced Ovarian Cancer

High-Grade Serous Ovarian Cancer: Molecular and Immune Diversity of mRNA Subtypes

ASCO 2025: A Noninvasive Diagnostic Tool for Ovarian Cancer

Research Focuses on How to Boost Immunotherapy Response in Recurrent Ovarian Cancer

Significant Overall Survival Benefit Seen With Mirvetuximab Soravtansine vs Chemotherapy in FRα-Positive, Platinum-Resistant Ovarian Cancer

RMAT Designation Granted by the FDA for Gemogenovatucel-T in Advanced Ovarian Cancer

FDA Grants Fast Track Designation to Novel Therapy for Platinum-Resistant Ovarian Cancer

Australian Clinical Trial to Assess Next-Generation Screening Test for Ovarian Cancer

View More

Advertisement

Published

Medical Literature

WEE1 Inhibitor Adavosertib Plus Gemcitabine in High-Grade Serous Ovarian Cancer

Does IgA Affect Antitumor Activity of Immune Cells in Ovarian Cancer?

Individualized Niraparib Dosing for Platinum-Sensitive Recurrent Ovarian Cancer

Chemotherapy Before or After Surgery in Advanced Ovarian Cancer: Comparing Outcomes

View More

Ongoing

CE Activities

Optimal integration of pembrolizumab into the care of patients with metastatic MSI-high/dMMR gynecologic cancers

Research experience with and ongoing evaluation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy or targeted therapy for advanced ovarian cancer

Addressing Persistent Challenges in Treatment and Management of Low-Grade Serous Ovarian Carcinoma to Amplify the Latest Evidence in Emerging Therapies

Evolution of the Care of Patients With Advanced Ovarian Cancer

View More

Available

Clinical Trials

City of Hope

Fox Chase Cancer Center

Fred Hutchinson Cancer Research Center

Helen Diller Family Comprehensive Cancer Center

View More

Resources

For Your Patients

CancerCare

Foundation for Women's Cancer

American Cancer Society

Rivkin Center for Ovarian Cancer

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2025 National Comprehensive Cancer Network, All Rights Reserved